Clinical-stage immune-oncology therapy developer CARsgen Therapeutics Holdings Limited announced on Monday that it has secured $186 million in a Series C round financing led by Loyal Valley Capital.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
